

#### **Introduction:**

Antimicrobial resistance (AMR) is "a global health security threat that requires action across government sectors and society as a whole" The World Health Organization (WHO) 1. In the United States alone, the Centers for Disease Control and Prevention (CDC) reports the excess direct healthcare costs due to AMR to be as high as \$20 billion, and additional lost for impacted less productivity is as high as \$35 billion a year 2.

## **Aims and Objectives:**

The aims and objectives of this study is to calculate incidence of colistin resistance in the hospital. This is a real and the highest level of threat currently looming in the whole world. The other objective is to see the organism wise resistance pattern and other antibiotic options we have.

All positive isolates were included from microbiology lab. Which includes both community and hospital acquired infections and all samples were included from respiratory tract, urine and blood. The isolates were screened for antimicrobial susceptibility testing by Kirby-Bauer disc diffusion method on Mueller-Hinton agar (Hi-Media) and interpreted as per CLSI guidelines. The duration of sample collection is taken w.e.f. January 2017 to October 2018.

#### **Results:**

A total of 2220 positive isolates were taken in the study, of which 20 isolates were found to be Colistin resistant (0.95%). The resistant pattern of various organisms is shown in below table.


Bacteria Colistin Resistant Total Cases Percentage

Klebsiella	11	52.38%
Pseudomonas	6	28.57%
E.Coli	3	14.29%
Acinetobactor	1	4.76%
Total	21	100%

#### Pattern of resistance:

Organism	Average 1	Lenath o	f stay (Days)	Outcome	(Mortality)
- 3		- 3			·

Klebsiella 31 22%





E.Coli	13	0%
Pseudomonas	43	20%
Acinetobactor	17	0%

#### **Discussion:**

In a four year cross-sectional study in Spain in 2017 where 13579 Enterobacteriaceae isolates were taken, it was found that 91 were colistin-resistant. The overall prevalence of colistin resistance was 0.67%. The rates were like this, Enterobacter cloacae (4.2%), Escherichia coli (0.5%) and Klebsiella pneumoniae (0.4%) 3. In one more study 3,902 *E. coli* isolates were studied in Italy and colistin resistance found to be 0.5% 4.

In a study in Tamilnadu, India they found the prevalence of colistin resistance is 28.72% 5. In our study we found overall prevalence of colistin was 0.95%. The commonest bug developing resistance is Klebsiella (52.38%) followed by Pseudomonas (28.57%), E.Coli (14.29%) and Acinetobactor (04.76%). Although the number is less but Pseudomonas has the maximum hospital length of stay (43 days) and significant mortality among all (20%). The overall mortality was seen highest with Klebsiella (22%). The sensitive antibiotics seen was widely variable but the common are Tigecycline, PolymyxinB, Doripenem, Imipenem, Meropenem, Fosfomycin, Minocycline etc. Three of Pseudomonas isolates from blood are found to be resistant to all antibiotics.


# Pattern according to isolates from blood, urine and respiratory tract:

Organism	Blood	Urine	Respiratory
Klebsiella	0	2	9
Pseudomonas	3	1	2
E.Coli	0	3	0
Acinetobactor	0	0	1

Klebsiella grew mainly in respiratory tract, Pseudomonas mainly in blood and E.Coli was seen mainly in urine. There was one colistin resistant isolate seen growing in respiratory tract.

#### **Conclusion:**

To conclude we should be aware of the danger looming above us regarding the emergence of colistin resistance and should focus on meticulous infection control measures and very





strict judicial use of these last weapon we have to fight against these tiny but most dangerous medical threat of the current era.

## **Declaration:**

The same group of isolates were taken in our other study "Emergence of Carbapenem resistance: A retrospective study in a tertiary care Centre in North East India". So this is the analysis of the colistin part. So the language and few other things are similar.

#### **References:**

- 1. Organization WH. Antimicrobial Resistance: Global Report on Surveillance. 2014; <a href="http://wwwwhoint/drugre-sistance/documents/surveillancereport/en/">http://wwwwhoint/drugre-sistance/documents/surveillancereport/en/</a>
- 2. Centers for Disease Control and Prevention. ANTIBIOTIC RESISTANCE THREATS in the United States, 2013. 2013; <a href="http://www.cdcgov/drugresistance/threat-report-2013/">http://www.cdcgov/drugresistance/threat-report-2013/</a>
- 3. Núria Prim, Miquel Turbau, Alba Rivera, Judith Rodríguez-Navarro, Pere Coll, Beatriz Mirelis, Prevalence of colistin resistance in clinical isolates of Enterobacteriaceae: A four-year cross-sectional study, Journal of Infection, Volume 75, Issue 6,2017, sciencedirect.
- 4. <a href="mailto:nfect Drug Resist">nfect Drug Resist</a>. 2018 Mar 9;11:377-385. doi: 10.2147/IDR.S160489. eCollection 2018. Multicenter prospective study on the prevalence of colistin resistance in *Escherichia coli*: relevance of *mcr-1*-positive clinical isolates in Lombardy, Northern Italy. <a href="mailto:Principe L1">Principe L1</a>, <a href="Piazza A2">Piazza A2</a>, <a href="mailto:Mauri C1">Mauri C1</a>, <a href="mailto:Anesi A4">Anesi A4</a>, <a href="mailto:Brigante G6">Brigante G6</a>, <a href="mailto:Casari E7">Casari E7</a>, <a href="mailto:Agrappi C8">Agrappi C8</a>, <a href="mailto:Caltagirone M2">Caltagirone M2</a>, <a href="mailto:Novazzi F2">Novazzi F2</a>, <a href="mailto:Migliavacca R2">Migliavacca R2</a>, <a href="Pagani L2">Pagani L2</a>, <a href="mailto:Luzzaro F1">Luzzaro F1</a>.
- 5. Nachimuthu, Ramesh & Manohar, Prasanth & Ramkumar, S & Mickymaray, Suresh & Tamhankar, Ashok & Gothandam, K M & Sivashanmugam, Karthikeyan & Bozdogan, Bülent. (2016). Colistin susceptibility of gram-negative clinical isolates from Tamil Nadu, India. 10. 35-39. 10.5372/1905-7415.1001.462.

#### **Author:**

#### Dr Apurba Kumar Borah

HOD & In-charge Emergency and Critical Care Medicine Narayana Superspeciality Hospital, Guwahati

## Dr. Vicky Lahkar

Consultant Microbiologist Narayana Superspeciality Hospital, Guwahati



# **Author**



View all posts